Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
arginine + glutamine + HMB
- Development stage
- Unknown
- Lead developer
- Abbott
- Modality
- Small Molecules
- Administration
- Oral, Tube-feed
01
Overview
Arginine + glutamine + HMB is a specialized nutritional combination consisting of the amino acids L-arginine and L-glutamine along with beta-hydroxy-beta-methylbutyrate (HMB), a metabolite of the branched-chain amino acid leucine. This combination is primarily developed as a Food for Special Medical Purposes (FSMP) or medical food to manage conditions characterized by muscle wasting (cachexia), impaired wound healing, and metabolic dysfunction. HMB acts by inhibiting muscle proteolysis and stimulating protein synthesis via the mTOR pathway. Arginine serves as a precursor for nitric oxide and growth hormone, while glutamine supports immune function and serves as a precursor for arginine and glutathione. Together, they synergistically promote collagen deposition and lean body mass preservation. Clinical applications include the treatment of AIDS-associated wasting, cancer cachexia, sarcopenia, and the reduction of visceral adipose tissue in obesity.
- Brand names
- AboundJuven
- Other names
- HMB/Arg/Glnarginine + glutamine + beta-hydroxy-beta-methylbutyrateL-arginine + L-glutamine + calcium beta-hydroxy-beta-methylbutyrate
02
Targets
NOS1 (nNOS)
Beyond the preview
Go deeper on arginine + glutamine + HMB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on arginine + glutamine + HMB.